Spero Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Spero Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 23% in 3 years; of every extra $100 of sales, $498 became extra profit. Higher than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$498Sales grew 23% in 3 years; of every extra $100 of sales, $498 became extra profit.
Higher than 93% of Healthcare companies in United States.
Asset Productivity Ratio
+23% / -45%In 3 years sales changed by +23% while total assets changed by -45%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-6.5×Operating cash was negative last year, while some debt falls due within a year.
Higher than 57% of Healthcare companies in United States.
Cash Cushion Ratio
+57%Cash, after subtracting all debt, equals 57% of its market value (net cash).
Higher than 79% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Spero Therapeutics, Inc. owes $0.16 for every $1 it owns. Spero Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
8.1Investors pay $8.1 for every $1 of Spero Therapeutics, Inc.'s yearly profit, lower than 83% of Healthcare companies in United States.
P/B ratio
1.49The share price is 1.49 times Spero Therapeutics, Inc.'s book value per share, lower than 68% of Healthcare companies in United States.
Market cap
$66 MThe total market value of all of Spero Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$44 MWhat Spero Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.76Net worth divided by the number of shares. The share price of $1.13 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
19.2%Spero Therapeutics, Inc. earned 19.2% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
Owes vs Owns
0.16×Spero Therapeutics, Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Dividend yield
NoneSpero Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+118%Revenue rose 118% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Profit growth
Back to profitSpero Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
14.4%Spero Therapeutics, Inc. keeps $14 of every $100 of revenue as net profit.
Cash quality
-1.5×Cash from Spero Therapeutics, Inc.'s business was -1.5× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Cash vs debt
Net cashSpero Therapeutics, Inc. held $37 M more cash than debt (net cash) at Dec 2025.
Questions
What is Spero Therapeutics, Inc.'s P/E ratio?
Investors pay $8.1 for every $1 of Spero Therapeutics, Inc.'s yearly profit, lower than 83% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Spero Therapeutics, Inc.: $66 M ÷ $44 M (30 Jun 2026) = 1.5.
What is Spero Therapeutics, Inc.'s return on equity?
Spero Therapeutics, Inc. earned 19.2% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
How much does Spero Therapeutics, Inc. owe compared with what it owns?
Spero Therapeutics, Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Does Spero Therapeutics, Inc. pay a dividend?
No. Spero Therapeutics, Inc. does not currently pay a dividend.
Is Spero Therapeutics, Inc.'s revenue growing?
Revenue rose 118% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.